MaxCyte (LON:MXCT) Shares Pass Below 50-Day Moving Average – Should You Sell?

MaxCyte, Inc. (LON:MXCT)’s stock price passed below its 50 day moving average during trading on Thursday . The stock has a 50 day moving average of GBX 298.81 ($3.88) and traded as low as GBX 273 ($3.54). MaxCyte shares last traded at GBX 279 ($3.62), with a volume of 2,555 shares changing hands.

MaxCyte Stock Performance

The firm’s 50 day simple moving average is GBX 297.25 and its 200-day simple moving average is GBX 325.43. The company has a debt-to-equity ratio of 8.37, a quick ratio of 14.38 and a current ratio of 14.31. The company has a market capitalization of £297.40 million, a price-to-earnings ratio of -1,088.46 and a beta of 1.13.

Insider Transactions at MaxCyte

In other news, insider Stan Erck sold 47,689 shares of the company’s stock in a transaction on Wednesday, October 2nd. The shares were sold at an average price of GBX 388 ($5.03), for a total value of £185,033.32 ($239,960.21). 1.45% of the stock is currently owned by company insiders.

MaxCyte Company Profile

MaxCyte, Inc, a life sciences company, discovers, develops, and commercializes next-generation cell therapies in the United States and internationally. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering.